



11 May 2020

### **Supplementary comments to March Quarterly Activities Report**

Further to the initial Quarterly Activities Report released by the company on 30 April 2020, the company makes the following additional comments in relation to its March quarter cash flows as disclosed in its Appendix 4C.

The Appendix 4C summarises the cash flows for the previous quarter which were not materially different to prior quarters other than:

- Material reduction in staff costs primarily due to the termination of US based staff
- Company incurred some one-off cost relating to its finance and administration support from its previous incumbent
- Income tax payable relating to FY2018 in respect of the subsidiary entity, Opyl Services (formerly The Social Science)
- Ongoing investment in its machine learning/artificial intelligence (AI) algorithm-based software interface as announced on 19 February 2020

Payments to related parties of the entity and their associates were made during the quarter. In total, approximately \$63,000 was paid to directors and associates for salaries, superannuation and R&D related contracted fees. This included costs of \$30,000 relating to the ongoing investment in the company's research and development of its clinical trial prediction software using AI.

The Board has authorised this announcement for release to the ASX.

**-ENDS-**

For media enquiries: Laura Blue +61 416 699 925

For investor enquiries: [info@opyl.ai](mailto:info@opyl.ai)

[www.opyl.ai](http://www.opyl.ai)

Opyl is a new generation company working at the intersection of artificial intelligence, social media and healthcare. Our focus is on developing digital tools that improve the healthcare experience for patients, deliver deep market insights from social media data and improve the efficiency and value of the clinical research process by employing artificial intelligence and emerging digital tools.

Our point of difference is the deep healthcare marketing and data science expertise of our diverse team and our understanding of real world data, particularly patient reported outcomes (PRO) and the continuous data and dialogue stream within consented social media.

Follow Opyl on Twitter (@Opylai), LinkedIn, Facebook and Instagram